TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.42
+6.09%Year over year
Reported trailing growth
- Revenue
- +49.4%
- EBITDA
- —
- EBIT
- -46.5%
- EPS
- -48.6%
- Free cash flow
- +268.7%
- Operating cash flow
- +401.3%
Forward estimates
Based on analyst estimates
- Revenue
- +67.3%
- EBITDA
- +554.5%
- EPS
- +282.7%
Three-year CAGR
- Revenue
- +64.9%
- EBITDA
- +108.4%
- EBIT
- +80.6%
- Net income
- +92.1%
- EPS
- +86.3%
- Free cash flow
- +94.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026